ARA-290 Introduction
ARA-290, a small peptide derived from erythropoietin's beta helix domain, extends beyond its known role in stimulating red blood cell production. Erythropoietin, produced in the kidney, has been recognized for its capacity to encourage blood vessel growth, support cell survival, impact blood pressure, and offer neuroprotective benefits in diabetic neuropathy. ARA-290 replicates EPO's neuroprotective and pain-relieving qualities without triggering red blood cell production. Phase II trials have been successfully completed, and preparations are underway for Phase III trials, exploring its potential in diabetes and the autoimmune condition sarcoidosis. Currently, ARA-290 is particularly promising for its ability to manage neuropathic pain, but ongoing research is investigating its potential as a wound repair stimulant in chronic diabetes, an immune-modulating medication, and a potential treatment for systemic lupus erythematosus (lupus or SLE).
Structure
Chemical composition and structural details of ARA-290
Sequence: ZEQLERALNSS
Molecular Formula: C51H84N16O21
Molecular Weight: 1257.3 g/mol
PubChem CID: 91810664
CAS Number: 1208243-50-8
Synonyms: cibinetide, PH-BS
Research
Blood Vessel Health
Retinal ischemia, a leading cause of blindness in developed countries, arises from various diseases. Protecting retinal epithelial cells from damage and promoting their regeneration could significantly reduce the disease's impact. Research in mice demonstrates that ARA-290 has the potential to shield endothelial colony-forming cells (ECFCs) from inflammation, thereby prolonging their survival and assisting in the repair and reconstruction of blood vessels.
Additional mouse studies indicate that ARA-290 enhances ECFCs' proliferation, migration, and lifespan throughout the vasculature. It also appears to enhance ECFCs' homing ability, enabling them to target areas of the vasculature requiring repair. There is optimism that this function could not only enhance the effectiveness of naturally occurring ECFCs but also improve the capability of transplanted ECFCs to repair blood vessels and restore circulation to ischemic tissue. If successful in ECFC transplants, ARA-290 may open up new avenues in medical therapy, enabling the successful transplantation of functional cells for tissue repair, hormone production, protein synthesis, and more.
Tissue Protection
The tissue-protective receptor (TPR) is found on various immune cells, including macrophages, dendritic cells, mast cells, and lymphocytes, notably T-cells. Emerging evidence indicates that ARA-290 and similar peptides can bind to this TPR on immune cells, directly influencing their function. In the case of macrophages, ARA-290’s stimulation of the TPR leads to a significant reduction in the release of proinflammatory cytokines like TNF-alpha and IL-6. Interestingly, while this dampening of the immune response may decrease pathogen clearance in certain situations, it also lowers disease severity and hinders the establishment of long-term disease processes. Research further suggests that TPR activation curbs the pathway of macrophage chemokine secretion, reducing the infiltration of inflammatory cytokines while enhancing the recruitment of tissue-resident macrophages to injury sites. The outcome appears to be improved tissue healing with fewer inflammatory side effects.
Additionally, studies indicate that ARA-290 may modify antigen presentation by dendritic cells, thus influencing adaptive immunity, which plays a role in long-term resistance against previously encountered pathogens. While this may initially seem concerning, it’s important to note that adaptive immunity primarily drives organ and tissue rejection following transplantation. The ability to modulate this process can help reduce graft rejection in various transplant scenarios, including kidney, heart, bone marrow, and experimental transplants.
ARA-290 holds promise in various medical applications. One particularly promising avenue is in the treatment of colitis, a condition that can result from infection or chronic autoimmune diseases like Crohn’s disease and ulcerative colitis. Current treatments for autoimmune colitis often involve injectable medications with numerous side effects. The use of more targeted immune modulators like ARA-290 could provide relief for individuals suffering from inflammatory bowel disease.
Another potential application of ARA-290’s immune modulatory effects is in treating systemic lupus erythematosus (SLE). Research in mice indicates that ARA-290 administration reduces levels of autoantibodies, such as ANA and anti-dsDNA, which serve as markers for SLE diagnosis and indicators of disease severity. Furthermore, ARA-290 diminishes kidney damage, a common source of morbidity and mortality in SLE. These findings suggest that ARA-290 may offer a highly targeted treatment option for SLE.
Summary
While ARA-290 has garnered significant attention for its innovative approach to managing neuropathic pain, it also holds promise for its immune-regulating properties, its capacity to promote wound healing, and its potential for protecting blood vessels during ischemic events. The most advanced area of research revolves around ARA-290's ability to modulate neuropathic pain. The peptide is currently undergoing phase II and III clinical trials for diabetic neuropathy and sarcoid neuropathy treatment, respectively. Additionally, there is growing interest in utilizing the peptide to treat conditions like systemic lupus erythematosus and pain syndromes associated with multiple sclerosis, HIV, celiac disease, and more. ARA-290 is also gaining attention as a potential disease-modifying agent in the context of inflammatory bowel disease.
ARA-290 has demonstrated minimal side effects, excellent subcutaneous bioavailability in mice, and is available for research purposes at Peptide Sciences. It is important to note that ARA-290 is intended solely for educational and scientific research and is not meant for human consumption. Purchases of ARA-290 should only be made by licensed researchers.
Article Author :
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Post time: 2026-06-10